Amenamevir (trade name Amenalief) is an
antiviral drug used for the treatment of
shingles (herpes zoster).
It acts as an inhibitor of the zoster virus's
helicase–primase complex.[1][2] Amenamevir was approved in Japan for the treatment of shingles in 2017.[3]
^Yajima M, Yamada H, Takemoto M, Daikoku T, Yoshida Y, Long T, et al. (March 2017). "Profile of anti-herpetic action of ASP2151 (amenamevir) as a helicase-primase inhibitor". Antiviral Research. 139: 95–101.
doi:
10.1016/j.antiviral.2016.12.008.
PMID28027917.
S2CID43813287.